COVID-19-associated ophthalmoparesis and hypothalamic involvement

Elba Pascual-Goñi, MD, Juan Fortea, MD, PhD, Alejandro Martínez-Domeño, MD, Nuria Rabella, MD, PhD, Mario Tecarne, MD, Cristina Gómez-Oliva, MD, PhD, Luis Querol, MD, PhD, and Beatriz Gómez-Ansón, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2020;7:e823. doi:10.1212/NXI.0000000000000823

SARS-CoV-2 is an emergent virus responsible for the coronavirus disease 2019 (COVID-19) outbreak. Reported neurologic manifestations associated with SARS-CoV-2 include hyposmia, headache, and consciousness disturbances.1 We describe 2 patients with COVID-19 presenting with ophthalmoparesis and characteristic MRI findings.

Case description

Case 1

A 60-year-old woman presented with diplopia and right hemicranial headache after 10 days of fever, hyposmia, nausea, and cough. Neurologic examination revealed right abducens nerve palsy. The patient was hypoxemic (PaO₂ 67 mm Hg) in the absence of dyspnea. Blood investigations showed lymphopenia (430/μL) and increased C-reactive protein (C-RP; 85 mg/L), with thiamine, pyridoxine, and D-dimer levels within the normal range. Chest x-ray revealed bilateral pneumonia. CSF showed 1 cell/mm³, normal protein levels (0.32 g/L), and elevated lactic acid dehydrogenase (LDH; 54 U/L). SARS-CoV-2 RNA was detected by RT-PCR in a nasopharyngeal swab specimen but not in CSF. Antiganglioside antibodies were negative, and oligoclonal bands were not detected in the CSF. Brain MRI (figure 1, A–D and figure e-1 links. lww.com/NXI/A276) showed diffuse fluid-attenuated inversion recovery (FLAIR)/T2-hyperintensity (HI) in the pontine tegmentum and focal HI in the right VI cranial nerve nuclei. The mammillary bodies and hypothalamus were HI, the pituitary gland was enlarged, and the upper pituitary stalk seemed globular. Treatment with hydroxychloroquine and azithromycin was started. Diplopia persisted 1 month after admission.

Case 2

A 35-year-old woman with a history of bulimia and a 3-week history of vomiting was admitted. During her hospital stay, she developed diplopia and paresthesia. Vomiting disappeared few days after admission, and she was discharged. Three days later, the patient presented with progressive encephalopathy and was again admitted. She had neither fever nor respiratory symptoms. Neurologic examination showed decreased arousal, disorientation, episodic memory deficits, bilateral abducens nerve palsy, and mild paraparesis with normal reflexes. Hypoxemia (PaO₂ 61 mm Hg), decreased lymphocytes (740/μL), increased C-RP (42 mg/L), and creatinine kinase (346 U/L) were detected; LDH, D-dimer, thiamine, pyridoxine, and ion levels were within the normal range. CSF revealed 0.53 g/L proteins, 2 cell/mm³, and normal LDH. Chest x-ray was normal. SARS-CoV-2 RNA was detected by RT-PCR in a nasopharyngeal swab specimen but not in CSF. Anti-AQP4 and antiganglioside antibodies were negative, and oligoclonal bands were not detected in the CSF. Brain MRI (figure 1, E–H and figure e-1) demonstrated T2/FLAIR HI in the brainstem, including the VI cranial nerve nuclei, thalamus, medial temporal lobes, mammillary bodies, and hypothalamus. The upper pituitary stalk seemed swollen and HI. The patient was diagnosed with Wernicke encephalopathy (WE) and was supplemented with...
thiamine and pyridoxine despite normal vitamin levels. The patient’s mental status partially improved during the following days. A control MRI (1 week after) also demonstrated partial improvement of the MRI findings. After 1 month, ophthalmoparesis and paraparesis as well as her mental status improved, but she had persistent episodic memory loss and depression.

Discussion

To our knowledge, these are the 2 first patients with COVID-19 presenting with ophthalmoparesis and involvement of the hypothalamus and mesencephalic tegmentum with some radiologic features resembling those of WE. However, thiamine levels in both our patients were normal, and there was no condition leading to thiamine deficiency in patient 1 and some radiologic features in case 2 (limbic involvement) were not typical of WE. Concurrency of both patients, both diagnosed with COVID-19, and the important hypothalamic involvement suggested a relationship with the underlying infection. Other cases of ophthalmoparesis associated with COVID-19 have recently been reported, one of them with enlargement and contrast enhancement of the oculomotor nerve that we did not observe in our patients. Acute hemorrhagic necrotizing encephalopathy has also been reported in association with confirmed COVID-19 on MRI. Similarly, encephalomyelitis associated with SARS-CoV-2 has been recently reported in a patient with unconsciousness and epileptic seizures in which SARS-CoV-2 was detected in the CSF, and MRI demonstrated T2-HI in the right medial temporal lobe. Our current cases show prominent hypothalamus and pituitary stalk involvement on MRI. Indeed, SARS-CoV (a related coronavirus causing the 2002–2004 SARS outbreak) has also been detected in hypothalamic neurons of SARS autopsies, and hypothalamic-pituitary-adrenal axis dysfunction has been observed in almost 40% of SARS survivors, suggesting that SARS-CoV could cause hypophysitis and/or hypothalamic damage. Furthermore, animal models have shown that after intranasal inoculations, SARS-CoV enters the brain through the olfactory bulb and via the olfactory nerve with subsequent trans-synaptic spread, causing selective neuronal infection and death in the absence of inflammation in the amygdala, raphe nuclei, and paramedial hypothalamus, a topographic distribution of lesions similar to that from our cases. The olfactory bulb involvement is supported by the high rates of hyposmia in patients with COVID-19 and would enable the trans-synaptic spread hypothesis. However, other mechanisms, arising from the inflammatory response or the metabolic demands to the susceptible regions, could also be playing a role in the development of our patients’ lesions.

In conclusion, we report 2 cases of COVID-19-associated neurologic manifestations with abducens palsy, encephalopathy, and characteristic MRI findings that suggest selective vulnerability of the involved regions. Whether this vulnerability is related to
direct viral tropism, the inflammatory cascade, or to an increase of local metabolic/vitamin demands remains to be elucidated.

**Study funding**
No targeted funding reported.

**Disclosure**
E.P.-G. received speaking fees from Roche and Biogen. J.F., A. M.-D., N.R., M.T., and C.G.-O. declare no conflicts. L.Q. has received speaker honoraria from Merck, Sanofi-Genzyme, Roche, Biogen, Grifols, and CSL Behring; provided expert testimony for Grifols, Johnson and Johnson, Annexin Pharmaceuticals, Alexion, Sanofi-Genzyme, Novartis, and CSL Behring; and received research funds from Roche and Grifols. B.G.-A. declares no conflicts. Go to Neurology.org/NN for full disclosures.

**Publication history**

### Appendix

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elba Pascual-Goñi, MD</td>
<td>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
<td>Conceptualized the study, acquired and analyzed the data, and drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Juan Fortea, MD, PhD</td>
<td>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
<td>Acquired and interpreted the data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Alejandro Martinez- Domeño, MD</td>
<td>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
<td>Interpreted the data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Nuria Rabella, MD, PhD</td>
<td>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
<td>Acquired and interpreted the data and revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

### References

COVID-19-associated ophthalmoparesis and hypothalamic involvement
Elba Pascual-Goñi, Juan Fortea, Alejandro Martínez-Domeño, et al.
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000823

This information is current as of June 25, 2020